Eurofins Central Laboratory

What Eurofins Central Laboratory does

Eurofins Central Laboratory (ECL) is a wholly-owned subsidiary of Eurofins Scientific SE, operating as a global central laboratory for Phase I-IV clinical trials. Founded in 1987 and headquartered at 2430 New Holland Pike, Lancaster, PA (operating entity: Eurofins Central Laboratory, LLC), the company maintains four wholly-owned harmonized laboratory facilities in Lancaster (USA), Breda (Netherlands), Singapore, and Shanghai (China), with additional kit packaging operations in Louisville (KY), Oosterhout (Netherlands), Shanghai, and a Bengaluru support office. It serves pharmaceutical companies, biotechnology firms, and Contract Research Organizations (CROs), supporting clinical trials in 85+ countries across six continents.

ECL's core service portfolio spans Routine Analysis, Biomarker Services, Specialty Testing (including genomics, pathology, and esoteric assays via Viracor Eurofins with 2,800+ validated assays), Project Management, Data Management, Sample Management (capacity exceeding 1 billion samples at -20°C and 1 million at -80°C), and Kit Manufacturing & Distribution (over 1 million kits produced annually). Underlying technology includes a single global LIMS database, the FETCH Data Portal for 24-hour secure data access, the EzRF web-based requisition tool, and DiscoveryAI SAFIRE — an AI-driven ADMET prediction platform trained on the proprietary BioPrint database (30 billion data points). The OmniGraf combination biomarker panel combines TruGraf gene expression testing with Viracor TRAC donor-derived cell-free DNA assays using machine learning for kidney transplant rejection detection.

ECL generates revenue primarily through professional services contracts for laboratory testing, with quote-based, custom-negotiated pricing for individual clinical trial engagements. Go-to-market is enterprise sales-led, targeting top pharmaceutical and biotech sponsors and CROs through dedicated sales teams and Global Lead Project Managers, with multi-year service agreements (e.g., five-year Emmes agreement signed 2021). Revenue is complemented by kit manufacturing and bioanalytical services through related group entities. The subsidiary operates within the Eurofins BioPharma Services division of Eurofins Scientific SE (Euronext Paris: ERF FP).

Name

Eurofins Central Laboratory

Legal name

Eurofins Central Laboratory, LLC

Website

https://eurofinscentrallaboratory.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

251–500 employees

Short description

Eurofins Central Laboratory is a global central laboratory providing Phase I-IV clinical trial testing for pharmaceutical, biotech, and CRO clients from four wholly-owned facilities in the USA, Netherlands, Singapore, and China, supported by kit manufacturing, sample management, and biomarker services across 85+ countries.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industries

Central Laboratory Services (Core Lab Operations) (HLAGAEAA), Clinical Research & Trial Central Laboratories (HLAFAMAL), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Clinical laboratory testing
• Central laboratory services
• Biomarker analysis
• Clinical trial support
• Bioanalytical services

Headquarters

HQ city

Lancaster

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Central Laboratory Testing Services: Core revenue stream from providing comprehensive clinical laboratory testing solutions for Phase I-IV clinical trials. Services include routine analysis, specialty testing, biomarker services, and pathology services for pharmaceutical and biotech companies, and CROs.
2. Bioanalytical Services: Method development, validation, and sample analysis for small and large molecule drug development including PK/TK, ADA, NAb, and biomarker assays for preclinical and clinical studies.
3. Kit Manufacturing & Distribution: Production and distribution of study and visit-specific specimen collection and transportation kits to investigator sites globally. Over 1 million kits produced annually.
4. Specialty Clinical Trial Laboratory Services: Complex/esoteric testing through Viracor Eurofins including molecular infectious disease testing, vaccine safety/efficacy, immunogenicity, cell-based assays, allergy/hypersensitivity, and biomarker analysis. Over 2800 validated assays available.
5. Sample Management & Storage: Sample storage services at various temperatures including ambient, 2-8°C, -20°C, -80°C, and liquid nitrogen. Storage capacity of more than 1 billion samples at -20°C and about 1 million at -80°C.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Eurofins Central Laboratory provides comprehensive central laboratory testing services for Phase I-IV clinical trials, including routine analysis, biomarker services, specialty testing, and pathology. The offering is delivered through four wholly-owned CAP/CLIA-certified harmonized facilities in the US, Netherlands, Singapore, and China, supported by a single global LIMS database, dedicated project management, kit manufacturing and logistics, and 24/5 investigator support for pharmaceutical, biotechnology, and CRO sponsors.

Product overview

Eurofins Central Laboratory is a pure-play leading Global Central Laboratory operating as part of the Eurofins BioPharma Services division. The company offers a unified platform-plus-services model consisting of core central laboratory testing (Routine Analysis, Biomarker Services, Specialty Testing, Pathology) complemented by integrated service modules (Project Management, Data Management with CDISC/SAS electronic data transfer, Investigator Services, Sample Management, Kits & Logistics with over 1 million annual kit production, and Innovation tools like EzRF requisition and home collection kits). Key diagnostic products include DiscoveryAI SAFIRE (AI-driven ADMET prediction platform), OmniGraf (kidney transplant rejection biomarker panel combining TruGraf and Viracor TRAC), and COVID-19 testing solutions (RT-PCR with FDA EUA and serology antibody tests). The portfolio also includes Viracor Eurofins specialty laboratory (2,800+ assays), Clinical Genomics (NGS, microarrays, pharmacogenomics), and Clinical Bioanalytical Services (PK/TK, ADA, biomarker assays). Four wholly-owned standardized laboratories in USA, Netherlands, Singapore, and China support global clinical trials across 85+ countries with CAP/CLIA certification.

Differentiator

Problem solved

Functional benefit

Products and services

• Central Laboratory Core Testing Services End-to-end central laboratory testing service for Phase I-IV clinical trials covering routine analysis, biomarker services, specialty testing, and pathology; delivered to pharmaceutical, biotech, and CRO sponsors from harmonized global facilities.
• Routine Analysis Routine safety, hematology, chemistry, and urinalysis testing performed as part of central lab services for clinical trials.
• Biomarker Services Specialized biomarker testing and assay development supporting targeted and exploratory clinical trial endpoints, including flow cytometry, immunohistochemistry, and pharmacogenomics.
• Specialty Testing Specialty and esoteric testing services providing more than 2,800 validated assays for clinical trials across infectious disease, immunology, allergy, oncology, and therapeutic drug monitoring.
• Pathology Global pathology services for clinical trials, including histology, biopsy, immunohistochemistry, and tissue-based diagnostic evaluations.
• DiscoveryAI SAFIRE AI/ML-driven drug discovery platform applying structure-based virtual screening and machine learning models against Eurofins' proprietary BioPrint database to accelerate compound discovery for pharmaceutical and biotech clients.
• OmniGraf Combination biomarker panel from Viracor Eurofins that combines TruGraf (gene expression) and Viracor TRAC (dd-cfDNA) with conventional biomarkers to assess kidney transplant rejection risk.
• TruGraf Blood gene expression test used as an alternative to surveillance biopsies for assessing subclinical kidney transplant rejection.
• Viracor TRAC

Quantifiable outcome

• CRO Leadership Award winner for 12 consecutive years in Capabilities, Compatibility, Quality, Reliability and Expertise
• +3 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature9 records

Partnerships

Five partnerships are on record, tiered core.

• EmmescoreStrategic or Co-development Partner · 30 September 2021Five-year service agreement extending existing relationship between Emmes and Eurofins Central Laboratory. Eurofins will provide global safety and efficacy testing and biomarker services in support of Emmes clinical drug development programs across vaccines, infectious diseases, ophthalmology, hematology, and rare diseases through Orphan Reach.
• Orphan ReachcoreStrategic or Co-development Partner · 30 September 2021Eurofins Central Laboratory provides rare disease clinical research support for Orphan Reach clinical trials through the five-year service agreement with parent company Emmes. Orphan Reach supports patients with rare diseases in more than 70 countries.
• Northwestern UniversitycoreStrategic or Co-development Partner · 27 September 2021Collaboration with Northwestern University on development of OmniGraf kidney transplant rejection diagnostic test. Dr. John Friedewald from Northwestern contributed to the development of the revolutionary test combining cell-free DNA and gene expression data for earliest kidney rejection detection.
• Transplant Genomics Inc.coreStrategic or Co-development Partner · 1 January 2021Transplant Genomics, part of Eurofins group, launched OmniGraf combining TruGraf blood gene expression test with Viracor TRAC donor-derived cell-free DNA assays. The partnership leverages machine learning and proprietary technology for kidney transplant rejection detection.
• National Kidney RegistrycoreStrategic or Co-development Partner · 1 January 2020Partnership for coronavirus COVID-19 rapid turnaround transplant testing for donors and recipients. Includes antibody testing services for transplant patients.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• IQVIA Central Laboratories: IQVIA operates global central laboratory services for clinical trials as part of its integrated CRO platform. Direct competitor to Eurofins Central Laboratory in routine, specialty, and biomarker testing for Phase I-IV trials.
• Fortrea (formerly LabCorp Drug Development / Covance Central Laboratory): Fortrea houses the former Covance Central Laboratory Services, a long-standing global central lab for clinical trials. Direct competitor in clinical trial central lab testing across all phases and therapeutic areas.
• ICON Central Laboratories: ICON provides global central laboratory services alongside its broader CRO offering after acquiring PRA Health Sciences. Direct competitor in clinical trial lab testing, biomarker services, and kit logistics.
• Syneos Health Central Laboratory: Syneos Health operates a global central laboratory network supporting clinical trials as part of its biopharmaceutical solutions platform. Direct peer in routine and specialty clinical trial testing.
• ACM Global Laboratories: ACM Global Central Laboratory is a specialty central lab focused on clinical trial testing. Smaller pure-play central lab with comparable service offering in routine safety, esoteric, and biomarker testing.
• MLM Medical Labs: MLM Medical Labs is a European-based central laboratory for clinical trials offering routine and specialty testing. Comparable in clinical trial focus, though smaller and more regionally concentrated than ECL.

Emerging players

• Medpace: Medpace is a mid-sized CRO with in-house central lab and imaging capabilities. Overlaps with ECL on clinical trial lab services, particularly in biomarker and specialty testing for biotech sponsors.

Broad incumbents

• Charles River Laboratories: Charles River is a large non-clinical and clinical CRO with broad life sciences services. Overlaps with ECL on bioanalytical, safety, and biomarker services for preclinical and clinical studies.
• Thermo Fisher Scientific PPD Central Labs: Thermo Fisher's PPD division operates global central lab services as part of its clinical research portfolio. Broader incumbent with deep pharma relationships and end-to-end trial delivery.
• Labcorp Diagnostics: Labcorp is a major clinical diagnostics network with overlap into clinical trial reference lab services. Indirect comparator — adjacent rather than direct — because its core is patient diagnostics, not central trial labs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eurofins-centrallaboratory

Compliance16 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eurofins Central Laboratory